Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the significance of the prolonged progression-free survival in patients with relapsed/refractory multiple myeloma (MM) if treating with isatuximab.
Advertisement